Clinical Trials Directory

Trials / Terminated

TerminatedNCT02778412

ctDNA in Patients With Thyroid Nodules

Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid

Status
Terminated
Phase
Study type
Observational
Enrollment
66 (actual)
Sponsor
Pathway Genomics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream. This circulating tumor DNA (ctDNA) can be detected by very sensitive, specialized laboratory tests. Measurement of ctDNA has been shown to be useful for following patients with known cancer. The purpose of this study is to examine blood specimens for the presence of ctDNA in individuals without known cancer who are scheduled to undergo a fine needle aspiration biopsy of the thyroid gland because of one or more thyroid nodules in order to see if the ctDNA test can detect a cancer at a very early stage. The results of this study should help define the role of ctDNA in the detection of early stage thyroid cancer and to define how sensitive it is (i.e. how well it picks up cancer when it is present) and how specific it is (i.e. how often is ctDNA found in patients with benign thyroid nodules).

Detailed description

After the participants with thyroid nodules or other abnormalities have undergone the informed consent process, they will have 30 milliliters (approximately two tablespoons) of blood drawn. This will be done prior to the performance of the fine needle aspiration biopsy of the thyroid. If the patient has indicated a desire to receive the results of their test, they will receive a written description, as will their physician. The patients will be contacted yearly for up to 5 years by the study staff to learn whether they have been found to have a diagnosis of thyroid or other cancer.

Conditions

Timeline

Start date
2016-05-01
Primary completion
2017-08-01
Completion
2017-08-01
First posted
2016-05-19
Last updated
2017-08-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02778412. Inclusion in this directory is not an endorsement.